Defendant
1 case as defendant.
Intas Pharmaceuticals Ltd. is a privately held Indian multinational pharmaceutical company founded in 1977 and headquartered in Ahmedabad, India. The company is majority-owned by the founding Chudgar family, with minority stakes held by Singapore's Temasek Holdings and private equity firm ChrysCapital. As one of India's largest privately owned pharmaceutical companies, Intas employs over 24,000 people and generated revenue of approximately $2.1 billion in fiscal year 2024.
Intas is a vertically integrated company focused on the development, manufacturing, and marketing of a wide range of pharmaceutical products. Its portfolio includes generic drugs, biosimilars, active pharmaceutical ingredients (APIs), and plasma-derived products. The company has a significant presence in numerous therapeutic areas, including oncology, cardiology, neurology, gastroenterology, and diabetology. Intas operates approximately 22 manufacturing facilities in India, the United Kingdom, Greece, and Mexico. A large portion of its revenue is generated from international markets, with a strong presence in Europe and North America through its subsidiary, Accord Healthcare.
As an operating company focused on generic and biosimilar drugs, Intas Pharmaceuticals' litigation profile shows it defending its products. The company has been tracked in one patent infringement case as a defendant in the U.S. District Court for the District of Delaware. This posture is typical for a generics manufacturer, which often faces litigation from brand-name drug companies when seeking approval to market generic versions of existing drugs.
The tracked case, Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. et al., was filed in 2022. The suit alleged that Intas and its subsidiary, Accord Healthcare, infringed on six patents related to Veloxis's organ transplant drug, ENVARSUS XR® (tacrolimus), by submitting an Abbreviated New Drug Application (ANDA) to the FDA to market a generic version. This type of litigation is a common feature of the pharmaceutical industry under the Hatch-Waxman Act.
The complaint alleged that the defendants' ANDA for generic tacrolimus extended-release tablets infringed on six Veloxis patents, including the '918 patent. Veloxis sought to block the manufacturing and marketing of the generic product.